These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15032645)

  • 21. Complement components of the innate immune system in health and disease in the CNS.
    Gasque P; Dean YD; McGreal EP; VanBeek J; Morgan BP
    Immunopharmacology; 2000 Aug; 49(1-2):171-86. PubMed ID: 10904116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of complement and perspectives for intervention in transplantation.
    Chen G; Chen S; Chen X
    Immunobiology; 2013 May; 218(5):817-27. PubMed ID: 23182708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-inflammatory drugs and the complement system. A condensation product of metacresolsulfonic acid and formaldehyde prevents instantly the complement activation in vitro.
    Gancevici GG; Popescu C
    Arch Roum Pathol Exp Microbiol; 1989; 48(2):157-62. PubMed ID: 2634368
    [No Abstract]   [Full Text] [Related]  

  • 24. Into the third century of complement research.
    Morgan BP; Daha M; Meri S; Nicholson-Weller A
    Immunol Today; 2000 Dec; 21(12):603-5. PubMed ID: 11188795
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.
    Barnum SR
    Mol Med; 1999 Sep; 5(9):569-82. PubMed ID: 10551898
    [No Abstract]   [Full Text] [Related]  

  • 26. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.
    Heesterbeek DAC; Angelier ML; Harrison RA; Rooijakkers SHM
    J Innate Immun; 2018; 10(5-6):455-464. PubMed ID: 30149378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.
    Rother RP; Mojcik CF; McCroskery EW
    Lupus; 2004; 13(5):328-34. PubMed ID: 15230287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement: the Iceman of immunology?
    Würzner R
    Immunopharmacology; 1997 Dec; 38(1-2):63-4. PubMed ID: 9476115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting C5a: recent advances in drug discovery.
    Allegretti M; Moriconi A; Beccari AR; Di Bitondo R; Bizzarri C; Bertini R; Colotta F
    Curr Med Chem; 2005; 12(2):217-36. PubMed ID: 15638737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycyrrhizin inhibits the lytic pathway of complement--possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis.
    Fujisawa Y; Sakamoto M; Matsushita M; Fujita T; Nishioka K
    Microbiol Immunol; 2000; 44(9):799-804. PubMed ID: 11092245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controlling the complement system for prevention of red cell destruction.
    Yazdanbakhsh K
    Curr Opin Hematol; 2005 Mar; 12(2):117-22. PubMed ID: 15725901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Membrane-targeted complement inhibitors.
    Smith GP; Smith RA
    Mol Immunol; 2001 Aug; 38(2-3):249-55. PubMed ID: 11532286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The future use of complement inhibitors for the treatment of neurological diseases.
    McGeer EG; McGeer PL
    Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement inhibition by anti-C5 antibodies--from bench to bedside and back again.
    Trendelenburg M
    Swiss Med Wkly; 2007 Jul; 137(29-30):413-7. PubMed ID: 17705103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of complement-derived mediators in inflammatory skin diseases.
    Tagami H
    Arch Dermatol Res; 1992; 284 Suppl 1():S2-9. PubMed ID: 1285651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate immunity and brain inflammation: the key role of complement.
    Francis K; van Beek J; Canova C; Neal JW; Gasque P
    Expert Rev Mol Med; 2003 May; 5(15):1-19. PubMed ID: 14585169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement-induced impairment of the innate immune system during sepsis.
    Albrecht EA; Ward PA
    Curr Allergy Asthma Rep; 2004 Sep; 4(5):359-64. PubMed ID: 15283874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.